Free Trial

Establishment Labs (ESTA) Competitors

-2.57 (-4.54%)
(As of 05/20/2024 ET)


Should you be buying Establishment Labs stock or one of its competitors? The main competitors of Establishment Labs include Avanos Medical (AVNS), Jin Medical International (ZJYL), Enovis (ENOV), Edgewise Therapeutics (EWTX), U.S. Physical Therapy (USPH), Kura Oncology (KURA), Supernus Pharmaceuticals (SUPN), Taro Pharmaceutical Industries (TARO), Spyre Therapeutics (SYRE), and Structure Therapeutics (GPCR). These companies are all part of the "medical" sector.

Establishment Labs vs.

Establishment Labs (NASDAQ:ESTA) and Avanos Medical (NYSE:AVNS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, community ranking, risk, earnings, profitability, media sentiment, institutional ownership, dividends and analyst recommendations.

Establishment Labs received 29 more outperform votes than Avanos Medical when rated by MarketBeat users. Likewise, 62.22% of users gave Establishment Labs an outperform vote while only 54.97% of users gave Avanos Medical an outperform vote.

Establishment LabsOutperform Votes
Underperform Votes
Avanos MedicalOutperform Votes
Underperform Votes

Establishment Labs currently has a consensus target price of $55.00, suggesting a potential upside of 1.85%. Avanos Medical has a consensus target price of $31.00, suggesting a potential upside of 52.56%. Given Avanos Medical's higher possible upside, analysts clearly believe Avanos Medical is more favorable than Establishment Labs.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Establishment Labs
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
Avanos Medical
0 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)

Avanos Medical has higher revenue and earnings than Establishment Labs. Establishment Labs is trading at a lower price-to-earnings ratio than Avanos Medical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Establishment Labs$155.79M9.54-$78.50M-$3.14-17.20
Avanos Medical$673.30M1.39-$61.80M-$1.33-15.28

Avanos Medical has a net margin of -9.15% compared to Establishment Labs' net margin of -53.12%. Avanos Medical's return on equity of 4.10% beat Establishment Labs' return on equity.

Company Net Margins Return on Equity Return on Assets
Establishment Labs-53.12% -206.05% -29.39%
Avanos Medical -9.15%4.10%2.99%

Establishment Labs has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500. Comparatively, Avanos Medical has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500.

72.9% of Establishment Labs shares are owned by institutional investors. Comparatively, 95.2% of Avanos Medical shares are owned by institutional investors. 11.4% of Establishment Labs shares are owned by insiders. Comparatively, 3.9% of Avanos Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Avanos Medical had 1 more articles in the media than Establishment Labs. MarketBeat recorded 2 mentions for Avanos Medical and 1 mentions for Establishment Labs. Establishment Labs' average media sentiment score of 1.75 beat Avanos Medical's score of 1.14 indicating that Establishment Labs is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Establishment Labs
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Avanos Medical
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)


Avanos Medical beats Establishment Labs on 10 of the 18 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ESTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ESTA vs. The Competition

MetricEstablishment LabsSurgical appliances & supplies IndustryMedical SectorNASDAQ Exchange
Market Cap$1.49B$8.88B$4.96B$7.99B
Dividend YieldN/A1.27%45.28%3.91%
P/E Ratio-17.2017.67136.7216.33
Price / Sales9.5448.542,472.7672.58
Price / CashN/A21.6132.4629.27
Price / Book76.
Net Income-$78.50M$177.27M$102.28M$212.79M
7 Day Performance-3.90%2.63%2.37%3.40%
1 Month Performance13.97%3.01%6.25%7.76%
1 Year Performance-21.31%-11.90%8.63%10.93%

Establishment Labs Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
Avanos Medical
3.9614 of 5 stars
Jin Medical International
0 of 5 stars
N/A-44.4%$522.35M$19.82M0.00269Positive News
2.9911 of 5 stars
Edgewise Therapeutics
1.637 of 5 stars
U.S. Physical Therapy
2.9316 of 5 stars
Kura Oncology
2.9222 of 5 stars
Supernus Pharmaceuticals
3.6408 of 5 stars
Taro Pharmaceutical Industries
0.999 of 5 stars
+43.4%$1.59B$572.95M34.701,554News Coverage
Spyre Therapeutics
0.6646 of 5 stars
N/A$1.58B$890,000.00-0.5530Earnings Report
Structure Therapeutics
1.799 of 5 stars

Related Companies and Tools

This page (NASDAQ:ESTA) was last updated on 5/20/2024 by Staff

From Our Partners